The International Biosecurity and Biosafety Initiative for Science (IBBIS) is proud to announce its membership in the International Gene Synthesis Consortium (IGSC).

IBBIS’s membership in the IGSC comes on the heels of launching the Common Mechanism, a free, open-source, globally-available tool for synthesis screening. IBBIS joins other providers of screening tools, including Battelle, RTX BBN, and Aclid, as members of the IGSC.

The Common Mechanism is designed to meet and exceed current screening guidance, including the IGSC Harmonized Screening Protocol. During beta testing, Twist Bioscience confirmed that the Common Mechanism enables users to screen orders in compliance with industry best practices. IBBIS’s membership in the IGSC will facilitate closer alignment between the Common Mechanism and the synthesis industry.

“Joining the IGSC allows us to further integrate the Common Mechanism with industry-wide efforts,” said Tessa Alexanian, the Tech Lead for the Common Mechanism. “We’re excited to collaborate on improving sequence and customer screening protocols across the field and around the world.”

As an IGSC member, IBBIS will actively participate in the consortium’s initiatives to advance global standards for nucleic acid synthesis screening. The organization remains committed to improving the Common Mechanism based on user feedback and evolving industry needs.

To learn more about the Common Mechanism, visit ibbis.bio/common-mechanism.